Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years

被引：0
|
作者：
Curtis, Jeffrey R. [1 ]
Wollenhaupt, Juergen [2 ]
Chatzidionysiou, Katerina [3 ]
Tas, Sander W. [4 ]
Wang, Lisy [5 ]
Shi, Harry [6 ]
Montoro, Maria [7 ]
Neregard, Petra [8 ]
Dahl, Palle [9 ]
Tsekouras, Vassilis [10 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Hamburg, Schon Klin Hamburg Eilbek Teaching Hosp, Hamburg, Germany
[3] Karolinska Inst, Div Rheumatol, Dept Med, Stockholm, Sweden
[4] Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[5] Pfizer Inc, Groton, CT 06340 USA
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer Inc, Madrid, Spain
[8] Pfizer Inc, Stochholm, Sweden
[9] Pfizer Inc, Ballerup, Denmark
[10] Pfizer Inc, Athens, Greece
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1519
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Pope, Janet E.
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Chapman, Douglass
    Haraoui, Boulos
    [J]. ACR OPEN RHEUMATOLOGY, 2019, 1 (02) : 73 - 82
  • [2] PERSISTENCE OF TOFACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES UP TO 7 YEARS
    Pope, J.
    Keystone, E.
    Jamal, S.
    Wang, L.
    Fallon, L.
    Woolcott, J.
    Lazariciu, I.
    Haraoui, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 245 - 245
  • [3] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    [J]. JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 879 - 879
  • [5] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    [J]. Arthritis Research & Therapy, 21
  • [6] Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years
    Curtis, Jeffrey R.
    Wollenhaupt, Jurgen
    Tas, Sander W.
    Chatzidionysiou, Katerina
    Wang, Lisy
    Roberts, Kevin
    Tsekouras, Vassilis
    [J]. RHEUMATOLOGY ADVANCES IN PRACTICE, 2024, 8 (02)
  • [7] Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Wollenhaupt, Juergen
    Lee, Eun-Bong
    Curtis, Jeffrey R.
    Silverfield, Joel
    Terry, Ketti
    Soma, Koshika
    Mojcik, Chris
    DeMasi, Ryan
    Strengholt, Sander
    Kwok, Kenneth
    Lazariciu, Irina
    Wang, Lisy
    Cohen, Stanley
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [8] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [9] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [10] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
12345